Poster

Assessment of Withdrawal Symptoms after Discontinuation of AXS-05 (Dextromethorphan-Bupropion) Treatment: Results from the GEMINI Trial

The GEMINI trial evaluated withdrawal symptoms in MDD patients after a 6-week treatment with AXS-05. Upon discontinuation, symptoms were assessed using the PWC-20. Results showed no signi...

Matthew J. Baker , PharmD;

10/26/2023

Adjunctive Brexpiprazole in Patients With Major Depressive Disorder Who Had One Prior Inadequate Antidepressant Including in a Subgroup With Energy/Concentration Symptoms

This post hoc pooled analysis of three randomized, fixed-dose, 6-week studies explored the efficacy of adjunctive brexpiprazole 2–3 mg/day in patients with major depressive disorder who h...

Shivani Kapadia ;

10/26/2023

Association between Anhedonia Severity and Clinical and Humanistic Outcomes Among US Adults with Major Depressive Disorder

This study examined the association of anhedonia severity with health-related outcomes among adults with major depressive disorder (MDD). The results showed that higher anhedonia scores w...

Tiina Drissen , PhD;

10/26/2023

Adjunctive Cariprazine in Patients With Major Depressive Disorder: A Post Hoc Analysis of Efficacy and Safety by Background Antidepressant Therapy

In this post hoc analysis, data from a phase 3 trial were used to evaluate adjunctive cariprazine versus adjunctive placebo by background ADT in patients with MDD and inadequate response ...

Majid Kerolous , PharmD, MPH;

10/26/2023

Agitation Associated with Schizophrenia or Bipolar Disorder: Sublingual Dexmedetomidine Film Efficacy by Baseline Agitation Level

Dexmedetomidine sublingual film reduced agitation symptoms as early as 20 minutes at 180mcg group and 30 minutes at 120mcg, regardless of baseline agitation severity.

Beth Chopp , PhD;

10/26/2023

Alternating Hemi-auto-prosopometamorphopsia (Cerebral Asthenopia) of Kith and Kin Mirror Hallucinations.

Prosopometamorphopsia has been noted to be one of the rare symptoms of schizophrenia. Our patient, with schizoaffective disorder, presented with hemi-autoprosopometamorphopsia with half o...

Shreya Dutt , MBBS;

10/26/2023

An Updated Meta-Analysis of the Clinical Utility of Combinatorial Pharmacogenomic Testing for Adult Patients with Depression

This updated meta-analysis investigating the clinical utility of combinatorial pharmacogenomic testing in adult patients (Nf3,532) with depression found that care guided by access to the ...

Melissa P. Dyer , PhD;

10/26/2023

A Phase 3, safety and efficacy, adult laboratory classroom study in subjects with Attention-Deficit/Hyperactivity Disorder (ADHD) using CTx-1301 (dexmethylphenidate).

Cingulate has conducted a Phase 3 randomized, placebo controlled efficacy and safety study along with onset and duration in 21 adults with ADHD using CTx-1301 in a laboratory classroom se...

Ann Childress , MD;

10/26/2023

A Pilot Study to Assess if Patients With Schizophrenia Can Form a Working Alliance With a Digital Therapeutic

Use of digital therapeutics has increased in recent years, but it is unclear if patients can establish an effective therapeutic digital working alliance (DWA) with digital therapeutic. In...

Nathan Mitchell , PhD;

10/26/2023

A Psychiatric Drug Prescription Framework to Predict Drug-Drug Interaction Risks with Artificial Intelligence

Using AI to streamline complex psychiatric drug prescriptions for more effective and safe clinical prognosis.

Danielle Wang ;

10/26/2023